CO5580738A2 - Procedimiento para modificar la formacion de cristal de farmaco - Google Patents
Procedimiento para modificar la formacion de cristal de farmacoInfo
- Publication number
- CO5580738A2 CO5580738A2 CO05072728A CO05072728A CO5580738A2 CO 5580738 A2 CO5580738 A2 CO 5580738A2 CO 05072728 A CO05072728 A CO 05072728A CO 05072728 A CO05072728 A CO 05072728A CO 5580738 A2 CO5580738 A2 CO 5580738A2
- Authority
- CO
- Colombia
- Prior art keywords
- crystal habit
- temperature oscillation
- procedure
- crystal
- farmaco
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
- C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Saccharide Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Furan Compounds (AREA)
Abstract
1.- Un procedimiento para modificar el hábito de cristal de una sustancia de fármaco acicular, que comprende suspender dicha sustancia de fármaco cristalina en un sistema de solvente que tiene un efecto sobre el hábito de cristal, y someter dicha suspensión a una oscilación de temperatura.2.- Un procedimiento para la recristalización de una sustancia de fármaco acicular, que comprende suspender dichos cristales en un sistema de solvente que tiene un efecto sobre el hábito de cristal, y someter dicha suspensión a una oscilación de temperatura.3.- El procedimiento de acuerdo con la reivindicación 1 ó 2, en donde el hábito de cristal es modificado ya que la relación de aspecto media de los cristales procesados es menor que aproximadamente 10:1.4.- El procedimiento de acuerdo con cualquiera de las reivindicaciones 1 a 3, en donde la sustancia del fármaco después de la oscilación de temperatura tiene una densidad aparente por arriba de aproximadamente 200 kg/m3.5.- El procedimiento de acuerdo con cualquiera de las reivindicaciones precedentes, en donde la oscilación de temperatura está en la forma de una curva de zigzag.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0301259.8A GB0301259D0 (en) | 2003-01-20 | 2003-01-20 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5580738A2 true CO5580738A2 (es) | 2005-11-30 |
Family
ID=9951448
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO05072728A CO5580738A2 (es) | 2003-01-20 | 2005-07-25 | Procedimiento para modificar la formacion de cristal de farmaco |
Country Status (32)
Country | Link |
---|---|
US (3) | US20060122265A1 (es) |
EP (2) | EP1592401B1 (es) |
JP (1) | JP4549976B2 (es) |
KR (5) | KR20100120321A (es) |
CN (2) | CN101333201A (es) |
AR (2) | AR043343A1 (es) |
AT (1) | ATE546132T1 (es) |
AU (1) | AU2004206731B2 (es) |
BR (1) | BRPI0406827A (es) |
CA (2) | CA2509796C (es) |
CL (1) | CL2004000073A1 (es) |
CO (1) | CO5580738A2 (es) |
CY (1) | CY1112772T1 (es) |
DK (1) | DK1592401T3 (es) |
EC (1) | ECSP055918A (es) |
ES (1) | ES2382035T3 (es) |
GB (1) | GB0301259D0 (es) |
HK (1) | HK1084874A1 (es) |
IL (1) | IL169484A (es) |
MX (1) | MXPA05007691A (es) |
MY (1) | MY148297A (es) |
NO (1) | NO20053846L (es) |
NZ (1) | NZ541073A (es) |
PE (2) | PE20040826A1 (es) |
PL (2) | PL376525A1 (es) |
PT (1) | PT1592401E (es) |
RU (1) | RU2388757C2 (es) |
SG (1) | SG155046A1 (es) |
SI (1) | SI1592401T1 (es) |
TW (1) | TWI325785B (es) |
WO (1) | WO2004064806A2 (es) |
ZA (1) | ZA200504442B (es) |
Families Citing this family (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0124953D0 (en) | 2001-10-17 | 2001-12-05 | Novartis Ag | Organic Compounds |
GB0301259D0 (en) | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
AR045957A1 (es) * | 2003-10-03 | 2005-11-16 | Novartis Ag | Composicion farmaceutica y combinacion |
WO2005105768A2 (en) | 2004-04-26 | 2005-11-10 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg | Process for preparation of mycophenolic acid and ester derivatives thereof |
WO2005105769A2 (en) | 2004-04-27 | 2005-11-10 | Teva Gyógyszergyár Zàrtköruen Muködo Rèszvènytàrsasàg - | Mycophenolate mofetil impurity |
CA2573781A1 (en) | 2004-07-20 | 2006-02-02 | Teva Gyogyszergyar Zartkoruen Mukodo Reszvenytarsasag | Processes for preparation of crystalline mycophenolate sodium |
GB0419355D0 (en) * | 2004-08-31 | 2004-09-29 | Novartis Ag | Organic compounds |
US20080176937A1 (en) * | 2007-01-23 | 2008-07-24 | Apotex Fermentation Inc. | Novel crystalline mycophenolate sodium polymorph and processes to manufacture same |
MX2011003731A (es) * | 2008-10-09 | 2011-08-03 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Uso de solventes organicos en la granulacion humeda de moxifloxacino. |
CN101756958B (zh) * | 2008-11-10 | 2011-07-20 | 鲁南制药集团股份有限公司 | 一种治疗关节炎的药物组合物及其制备方法 |
US20110009347A1 (en) | 2009-07-08 | 2011-01-13 | Yin Liang | Combination therapy for the treatment of diabetes |
EP2451797B1 (en) | 2009-07-10 | 2013-04-03 | Janssen Pharmaceutica, N.V. | CRYSTALLISATION PROCESS FOR 1-(ß-D-GLUCOPYRANOSYL)-4-METHYL-3-[5-(4-FLUOROPHENYL)-2-THIENYLMETHYL]BENZENE |
EP2488173A1 (en) * | 2009-10-13 | 2012-08-22 | Teva Pharmaceutical Industries Ltd. | Delayed release compositions |
EP3378854B1 (en) | 2010-01-27 | 2022-12-21 | Arena Pharmaceuticals, Inc. | Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof |
CN108354930A (zh) | 2010-05-11 | 2018-08-03 | 詹森药业有限公司 | 包含1-(β-D-吡喃葡萄糖基)-2-噻吩基-甲基苯衍生物的药物制剂 |
CN103880800A (zh) * | 2010-11-16 | 2014-06-25 | 北京京卫信康医药科技发展有限公司 | 麦考酚酸钠的新晶型及其制备方法 |
CN103880799A (zh) * | 2010-11-16 | 2014-06-25 | 北京京卫信康医药科技发展有限公司 | 麦考酚酸钠的新晶型及其制备方法 |
HUE030116T2 (en) | 2011-04-13 | 2017-04-28 | Janssen Pharmaceutica Nv | A method for preparing compounds useful as inhibitors of SGLT2 |
TWI582078B (zh) * | 2013-01-23 | 2017-05-11 | 北京貝美拓新藥研發有限公司 | 抑制脯氨酸羥化酶活性的化合物的晶型及其應用 |
SI3310760T1 (sl) | 2015-06-22 | 2023-02-28 | Arena Pharmaceuticals, Inc. | Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1 |
US20170071970A1 (en) | 2015-09-15 | 2017-03-16 | Janssen Pharmaceutica Nv | Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders |
PL3394051T3 (pl) * | 2015-12-21 | 2020-10-19 | Janssen Pharmaceutica N.V. | Procedura krystalizacji do otrzymywania kryształów półwodnej kanagliflozyny |
KR20190116416A (ko) | 2017-02-16 | 2019-10-14 | 아레나 파마슈티칼스, 인크. | 원발 담즙성 담관염을 치료하기 위한 화합물 및 방법 |
MA47503A (fr) | 2017-02-16 | 2021-04-21 | Arena Pharm Inc | Composés et méthodes pour le traitement de maladies inflammatoires chroniques de l'intestin avec manifestations extra-intestinales |
CN108727317A (zh) * | 2017-04-25 | 2018-11-02 | 鲁南制药集团股份有限公司 | 一种麦考酚酸的晶型物 |
CN108727318A (zh) * | 2017-04-25 | 2018-11-02 | 鲁南制药集团股份有限公司 | 麦考酚酸的晶型物 |
CN110922371B (zh) * | 2019-12-27 | 2020-08-11 | 广东蓝宝制药有限公司 | 一种m2晶型麦考酚钠的制备方法 |
WO2023234158A1 (ja) * | 2022-05-31 | 2023-12-07 | 本州化学工業株式会社 | 4,4'-ビス(1,1-ビス(4-ヒドロキシ-3-メチルフェニル)エチル)ビフェニルの結晶及び、その製造方法 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US158835A (en) * | 1875-01-19 | Improvement in mortising-tools | ||
GB935432A (en) * | 1958-05-29 | 1963-08-28 | Secr Aviation | Improvements in the manufacture of crystalline substances |
US3187039A (en) * | 1962-10-19 | 1965-06-01 | Commercial Solvents Corp | Method for changing the crystal habit of monosodium glutamate |
US3183263A (en) * | 1962-10-19 | 1965-05-11 | Commercial Solvents Corp | Method for changing the crystal habit of mono-sodium glutamate |
US3352906A (en) * | 1963-02-04 | 1967-11-14 | Charles R Parkerson | Habit modification and preparation of single crystal triglycine sulfate |
US3770390A (en) * | 1971-02-26 | 1973-11-06 | Dow Chemical Co | Crystal habit modification of inorganic salts using polymeric sulfonates or sulfates |
US4259239A (en) * | 1980-04-21 | 1981-03-31 | Allied Chemical Corporation | Resolution of enantiomeric complexes of nickelous chloride and alpha-aminocaprolactam |
IL60254A (en) | 1980-06-08 | 1983-11-30 | Yeda Res & Dev | Resolution of amino acids |
JPS5875194A (ja) * | 1981-10-30 | 1983-05-06 | 株式会社日立製作所 | マトリクス表示装置及び駆動方法 |
JPS59232916A (ja) * | 1983-06-16 | 1984-12-27 | Shiraishi Chuo Kenkyusho:Kk | 針柱状炭酸カルシウム結束体、その製造法及び該結束体を含有する感熱紙用塗被組成物 |
IL77031A (en) | 1985-11-12 | 1995-12-08 | Yeda Res & Dev | Kinetic resolution of racemic mixtures by polymer-bound crystallization inhibitors |
JPH0745359B2 (ja) | 1987-12-25 | 1995-05-17 | 東レ株式会社 | 有機化合物結晶の製造方法 |
DE69321531T2 (de) * | 1992-08-04 | 1999-03-04 | Toda Kogyo Corp | Granulierte Teilchen für magnetische Teilchen für magnetische Aufzeichnung und Verfahren für ihre Herstellung |
DK0724581T3 (da) | 1993-09-15 | 1999-08-02 | Syntex Inc | Krystallinsk vandfri mycophenolatmofetil og intravenøs formulering deraf |
JPH09209297A (ja) * | 1996-01-26 | 1997-08-12 | Nippon Paper Ind Co Ltd | 艶消し軽量塗工紙及びその製造方法 |
ID18663A (id) | 1996-04-12 | 1998-04-30 | Novartis Ag | Komposisi farmasi berlapis enterik |
KR100491274B1 (ko) * | 1996-04-12 | 2005-09-05 | 노파르티스 아게 | 미코페놀레이트의장용코팅된약제조성물 |
FR2780403B3 (fr) * | 1998-06-24 | 2000-07-21 | Sanofi Sa | Nouvelle forme de l'irbesartan, procedes pour obtenir ladite forme et compositions pharmaceutiques en contenant |
GB0301259D0 (en) * | 2003-01-20 | 2003-02-19 | Novartis Ag | Organic compounds |
-
2003
- 2003-01-20 GB GBGB0301259.8A patent/GB0301259D0/en not_active Ceased
-
2004
- 2004-01-19 SI SI200431859T patent/SI1592401T1/sl unknown
- 2004-01-19 CA CA2509796A patent/CA2509796C/en not_active Expired - Lifetime
- 2004-01-19 PE PE2004000074A patent/PE20040826A1/es not_active Application Discontinuation
- 2004-01-19 KR KR1020107024515A patent/KR20100120321A/ko not_active Application Discontinuation
- 2004-01-19 TW TW093101302A patent/TWI325785B/zh not_active IP Right Cessation
- 2004-01-19 KR KR1020097022061A patent/KR101129105B1/ko active IP Right Grant
- 2004-01-19 KR KR1020057013313A patent/KR100855149B1/ko active IP Right Grant
- 2004-01-19 EP EP04703158A patent/EP1592401B1/en not_active Revoked
- 2004-01-19 SG SG200700660-4A patent/SG155046A1/en unknown
- 2004-01-19 BR BR0406827-0A patent/BRPI0406827A/pt not_active Application Discontinuation
- 2004-01-19 CN CNA2008101443548A patent/CN101333201A/zh active Pending
- 2004-01-19 AT AT04703158T patent/ATE546132T1/de active
- 2004-01-19 PT PT04703158T patent/PT1592401E/pt unknown
- 2004-01-19 JP JP2005518641A patent/JP4549976B2/ja not_active Expired - Fee Related
- 2004-01-19 ES ES04703158T patent/ES2382035T3/es not_active Expired - Lifetime
- 2004-01-19 PE PE2011000069A patent/PE20110276A1/es active IP Right Grant
- 2004-01-19 PL PL376525A patent/PL376525A1/pl not_active Application Discontinuation
- 2004-01-19 RU RU2005126328/04A patent/RU2388757C2/ru active
- 2004-01-19 PL PL393385A patent/PL213192B1/pl unknown
- 2004-01-19 MX MXPA05007691A patent/MXPA05007691A/es active IP Right Grant
- 2004-01-19 KR KR1020097022060A patent/KR20090115821A/ko active Search and Examination
- 2004-01-19 MY MYPI20040142A patent/MY148297A/en unknown
- 2004-01-19 WO PCT/EP2004/000354 patent/WO2004064806A2/en active Application Filing
- 2004-01-19 KR KR1020077016703A patent/KR20070087181A/ko not_active Application Discontinuation
- 2004-01-19 NZ NZ541073A patent/NZ541073A/en not_active IP Right Cessation
- 2004-01-19 EP EP10177718A patent/EP2308471A1/en not_active Withdrawn
- 2004-01-19 US US10/541,504 patent/US20060122265A1/en not_active Abandoned
- 2004-01-19 AU AU2004206731A patent/AU2004206731B2/en not_active Expired
- 2004-01-19 AR ARP040100142A patent/AR043343A1/es unknown
- 2004-01-19 CA CA2706900A patent/CA2706900A1/en not_active Abandoned
- 2004-01-19 CN CN200480002455A patent/CN100595199C/zh not_active Expired - Lifetime
- 2004-01-19 DK DK04703158.8T patent/DK1592401T3/da active
- 2004-01-20 CL CL200400073A patent/CL2004000073A1/es unknown
-
2005
- 2005-05-31 ZA ZA200504442A patent/ZA200504442B/en unknown
- 2005-06-30 IL IL169484A patent/IL169484A/en active IP Right Grant
- 2005-07-15 EC EC2005005918A patent/ECSP055918A/es unknown
- 2005-07-25 CO CO05072728A patent/CO5580738A2/es not_active Application Discontinuation
- 2005-08-16 NO NO20053846A patent/NO20053846L/no not_active Application Discontinuation
-
2006
- 2006-04-26 HK HK06104995.1A patent/HK1084874A1/xx not_active IP Right Cessation
-
2008
- 2008-12-18 US US12/337,663 patent/US8008511B2/en not_active Expired - Lifetime
-
2011
- 2011-08-04 US US13/198,022 patent/US8124795B2/en not_active Expired - Lifetime
-
2012
- 2012-05-14 CY CY20121100450T patent/CY1112772T1/el unknown
-
2016
- 2016-02-15 AR ARP160100409A patent/AR103711A2/es not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5580738A2 (es) | Procedimiento para modificar la formacion de cristal de farmaco | |
BR0209433A (pt) | Método para realizar cristalização, e, aparelho | |
BRPI0409905A (pt) | forma cristalina aperfeiçoada de sucralose, e método para produzir a mesma | |
AR038648A1 (es) | Hormona paratiroidea en forma cristalina y proceso para purificar la hormona paratiroidea y obtener dicha forma cristalina | |
NO20075331L (no) | Innretning og fremgangsmate for krystallisering av ikke-jernholdige metaller. | |
AR048073A2 (es) | 40-o-(2-hidroxi-etil)-rapamicina, proceso para su produccion y composicion farmaceutica que la contiene | |
EA200300944A1 (ru) | Ацилированные пиперидиновые производные в качестве агонистов рецептора-4 меланокортина | |
ATE211508T1 (de) | Verfahren zur rueckgewinnung einer organischen verbindung aus loesungen | |
JP2016222678A5 (es) | ||
DK1173265T3 (da) | Apparat og fremgangsmåde til krystallisation med ultralydstråler | |
EP1559814A4 (en) | PROCESS FOR PRODUCING CRYSTALLINE CORE AND METHOD FOR SCREENING CRYSTALLIZATION CONDITIONS | |
MX169369B (es) | Proceso para la produccion continua de monoisocianato o poliisocianato organicos | |
DE502007006907D1 (de) | Verfahren und vorrichtung zur herstellung und behandlung von granulatkörnern | |
PA8781201A1 (es) | "proceso mejorado par la elaboración de hidrazidas" | |
CR7783A (es) | Metodo de purificacion de lantibioticos | |
ATE403658T1 (de) | Verfahren zur herstellung einer lösung von reinem triethylendiamin (teda) | |
Shiba et al. | Calaxin is required for asymmetric bend initiation and propagation in sperm flagella | |
MX167808B (es) | Metodo para separar hidrocloruro de l-cisteina munhidratado | |
BRPI0415585A (pt) | processo para a cristalização de um produto de oxidação | |
FI20001655A (fi) | Kiteytysmenetelmõ | |
BR112015014485A2 (pt) | método e aparelho para expandir um produto que contém amido | |
ES2146386T3 (es) | Procedimiento de obtencion de sal, en especial de cloruro de potasio, por lixiviacion y enfriamiento de la solucion. | |
Wang et al. | SECONDARY NUCLEATION OF∊-CAPROLACTAM IN TOLUENE SOLUTION BY FLUID SHEAR FORCES | |
Houghton et al. | Time to establish a New Zealand/Aotearoa Twin Registry? | |
Youngquist | Convective effects on secondary nucleation and growth |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Application refused |